Haplo-SCT plus dinutuximab beta ‘feasible’ for relapsed high-risk neuroblastoma
Children with relapsed, high-risk neuroblastoma may benefit from immunotherapy with dinutuximab beta after haploidentical stem-cell transplantation, investigators write in the Journal of Clinical Oncology.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
